References:
†Allergan. Data on File. REF-96563. FILLERS GLOBAL NUMBER OF SYRINGES. 100 million Juvéderm®️ syringes manufactured worldwide from 2004 to April 2022. May 2022.
^Allergan. Unpublished Data. INT/0771/2016(2). JUVÉDERM®️, the world’s leading brand of hyaluronic acid facial fillers. Feb 2019.
1. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e;
2. De Maio M, et al. Plast Reconstr Surg. 2017 Oct;140(4):540e-550e;
3. De Maio M. et. al. Plast Reconstr Surg. 2017 Sep;140(3):393e-404e;
4. Ogilvie P et al. J Cosmetic Dermatol. 2019;00:1-6
5. Callan P et al. Clin Cosmet Investig Dermatol. 2013;6:81-9
6. VOLUXTM, VOLUMA®️, VOLIFT®️ 及 VOLBELLA®️ (approval as VOLUXTM XC, VOLUMA®️ XC, VOLLURE®️ XC and VOLBELLA®️ XC in US) 均獲得美國 FDA 認證. U.S. Food and Drug Administration, Department of Health & Human Services. Juvéderm VOLUX XC approval letter P110033/S065, July 2022; Juvéderm VOLUMA XC approval letter P110033/S047, Jun 2020; Juvéderm VOLLURE XC approval letter P110033/S020, Mar 2017; Juvéderm VOLBELLA XC approval letter P110033/S053, May 2021.
7. VOLUX™️, VOLUMA®️, VOLIFT®️, VOLBELLA®️ 及 VOLITE™️均獲得歐盟 CE 認證. European Commission, Juvéderm hyaluronic acid based medical devices. EC certificate number: 3824296CE02; 3824296CE05; 3824296CE06; 3824296CE08; 3824296CE09, Mar 2020.
8. Goodman GJ et al. Plast Reconstr Surg. 2015;136(5 Suppl):139–48;
9. Lebreton P. 2004. WO2004092222A2. Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and hydrogels thus obtained